DV
Dividend Vision

RAPP — Rapport Therapeutics, Inc.

Rapport Therapeutics, Inc. (RAPP)

Total return is 128.0% over the past 2.2 years, 78.7 points ahead of SPY at 49.3%. Its deepest 1-year drawdown was 28.8%.

RAPP is a single-stock equity fund that tracks Rapport Therapeutics, Inc., a clinical-stage biopharmaceutical company. The fund does not currently distribute dividends, making it unsuitable for income-focused investors seeking regular cash distributions. This fund structure appeals primarily to investors seeking direct exposure to a specific therapeutic company's stock performance rather than diversified dividend income.

RAPP key facts

Asset type
Stock
Asset class
Equity
Inception date
06/07/2024
Distribution frequency
None
Last close
$47.42
Market cap
$2,275,130,368
Average volume
159831.0
Beta
0.971
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.03